Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Market Access
  • The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
  • Market Access

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)

Drug Channels

This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: PBM Industry Update 2026: Trends, Challenges, and What's Ahead .

Market AccessRead full story

pharminent April 6, 2026 (Last updated: April 6, 2026)

Drug Channels

This week, we’re rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .

Market AccessRead full story

Post navigation

Previous: Aspect Biosystems receives funding for cellular medicine project
Next: Pharma Pipeline Stalls for First Time in Decades: Citeline

Related Stories

  • Market Access

Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing

pharminent September 2, 2026
  • Market Access

How cost and perception could reshape the GLP-1 market

pharminent August 21, 2026
  • Market Access

D.C. Circuit Affirms HHS Authority Over 340B Rebate Models

pharminent July 24, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.